LYELL EPI-R Trademark

Trademark Overview


On Wednesday, December 15, 2021, a trademark application was filed for LYELL EPI-R with the United States Patent and Trademark Office. The USPTO has given the LYELL EPI-R trademark a serial number of 97173223. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Wednesday, July 17, 2024. This trademark is owned by Lyell Immunopharma, Inc.. The LYELL EPI-R trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:

Medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer

Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells, in the field of cancer treatment, auto-immune diseases, and infectious diseases; scientific and technological services and biological research and development, namely, research and development in the field of the treatment of cancer
lyell epi-r

General Information


Serial Number97173223
Word MarkLYELL EPI-R
Filing DateWednesday, December 15, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateWednesday, July 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 6, 2022

Trademark Statements


Goods and ServicesMedical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer
Goods and ServicesScientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells, in the field of cancer treatment, auto-immune diseases, and infectious diseases; scientific and technological services and biological research and development, namely, research and development in the field of the treatment of cancer

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, November 1, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, December 20, 2021
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameLyell Immunopharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Party NameLyell Immunopharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events


Event DateEvent Description
Thursday, September 22, 2022NON-FINAL ACTION WRITTEN
Saturday, December 18, 2021NEW APPLICATION ENTERED
Monday, December 20, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 21, 2022ASSIGNED TO EXAMINER
Thursday, September 22, 2022NON-FINAL ACTION E-MAILED
Thursday, September 22, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 1, 2022EXAMINERS AMENDMENT -WRITTEN
Thursday, October 20, 2022ASSIGNED TO EXAMINER
Tuesday, November 1, 2022EXAMINERS AMENDMENT E-MAILED
Tuesday, November 1, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, November 1, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, November 2, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 16, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 6, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 6, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 31, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, July 27, 2023SOU EXTENSION 1 FILED
Thursday, July 27, 2023SOU EXTENSION 1 GRANTED
Saturday, July 29, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 27, 2023SOU TEAS EXTENSION RECEIVED
Monday, January 29, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 31, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 17, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 17, 2024SOU EXTENSION 3 GRANTED
Wednesday, July 17, 2024SOU EXTENSION 3 FILED
Monday, January 29, 2024SOU EXTENSION 2 GRANTED
Monday, January 29, 2024SOU EXTENSION 2 FILED